ROS1 and non-small cell lung carcinoma: Furthermore, combinational therapy with crizotinib, which is a MET/ALK/ROS1 TKI, with selpercatinib in patients who had RET fusion-positive and MET-amplified NSCLC showed clinical efficacy in selpercatinib-resistant tumors [40].